Phath­om Phar­ma­ceu­ti­cals snatch­es up an­oth­er Cel­gene ex­ec; True North bets $74M for a stake in Bio­con Bi­o­log­ics

→ Ahead of the po­ten­tial com­mer­cial­iza­tion of vono­prazan, gas­troin­testi­nal dis­ease-fo­cused Phath­om Phar­ma­ceu­ti­cals has brought on an­oth­er for­mer Cel­gene ex­ec. Last month the com­pa­ny wel­comed Ter­rie Cur­ran to the CEO role, and now, Phath­om has tapped Mar­tin Gilli­gan as CCO. Gilli­gan most re­cent­ly served as cor­po­rate vice pres­i­dent, glob­al mar­ket­ing and mar­ket ac­cess for Cel­gene’s in­flam­ma­tion and im­munol­o­gy fran­chise and is hailed for help­ing guide the launch and growth of Ote­zla up through its $13.5 bil­lion sale to Am­gen. His pre­vi­ous stints in­clude roles at Phar­ma­cia, J&J and Mer­ck.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER